Table 1.
Characteristics of 47 enrolled patients.
| Characteristics | All patients (N = 47) | Recovered (N = 35) | Dead (N = 12) |
|---|---|---|---|
| Age, median (range) | 59 (33–82) | 55 (33–77) | 64 (53–82) |
| Sex | |||
| Male | 29/47 (61.7) | 21/35 (60) | 8/12 (66.67) |
| Female | 18/47 (38.3) | 14/35 (40) | 4/12 (33.33) |
| Clinical severity | |||
| Mild | 10/47 (21.28) | 10/35 (28.57) | 0 |
| Severe | 37/47 (78.72) | 25/35 (71.43) | 12 (100) |
| Symptoms | |||
| Fever | 39/47 (82.98) | 31/35 (88.57) | 8/12 (66.67) |
| Dry cough | 39/47 (82.98) | 31/35 (88.57) | 8/12 (66.67) |
| Dyspnea | 34/47 (72.34) | 25/35 (71.43) | 9/12 (75) |
| Myalgia | 20/47 (42.55) | 16/35 (45.71) | 4/12 (33.33) |
| Acute respiratory insufficiency | 10/47 (21.28) | 7/35 (20) | 3/12 (25) |
| Headache | 6/47 (12.77) | 6/35 (17.14) | 0 |
| Thromboembolism | 5/47 (10.64) | 4/35 (11.43) | 1/12 (8.33) |
| Diarrhea | 4/47 (8.52) | 3/35 (8.57) | 1/12 (8.33) |
| Pneumonia | 3/47 (6.39) | 3/35 (8.57) | 0 |
| Chill | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
| Asthenia | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
| Odynophagia | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Nasal obstruction | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Respiratory distress | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Dysuria | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Sweating | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Anosmia | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Sore throat | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Malaise | 1/47 (2.13) | 0 | 1/12 (8.33) |
| Hyporexia | 1/47 (2.13) | 0 | 1/12 (8.33) |
| Coexisting disorders | |||
| Obesity | 25/47 (53.19) | 17/35 (48.57) | 8/12 (66.67) |
| Hypertension | 23/47 (48.94) | 17/35 (48.57) | 6/12 (50) |
| Diabetes | 16/47 (30.04) | 11/35 (31.43) | 5/12 (41.67) |
| HIV | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
| Deep vein thrombosis | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
| COPD | 3/47 (6.39) | 2/35 (5.71) | 1/12 (8.33) |
| Hypothyroidism | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
| Prostatic hypertrophy | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
| Stroke | 2/47 (4.26) | 1/35 (2.86) | 1/12 (8.33) |
| Asthma | 2/47 (4.26) | 2/35 (5.71) | 0 |
| Pre-existing lesions | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Tinea cruris | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Sleep apnea | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Epilepsy | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Hepatitis B | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Encephalitis | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Cardiac insufficiency | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Kidney transplant | 1/47 (2.13) | 1/35 (2.86) | 0 |
| None | 4/47 (8.52) | 4/35 (11.43) | 0 |
| Treatment | |||
| Antibiotics | 45/47 (95.74) | 33/35 (94.29) | 12 (100) |
| Antiviral | 24/47 (51.06) | 17/35 (48.57) | 7/12 (58.33) |
| Corticoids | 16/47 (30.04) | 12/35 (34.29) | 4/12 (33.33) |
| Anticoagulants | 13/47 (27.67) | 10/35 (28.57) | 3/12 (25) |
| Chloroquine | 9/47 (19.15) | 7/35 (20) | 2/12 (16.67) |
| Immunosuppressant | 1/47 (2.13) | 1/35 (2.86) | 0 |
| Vasodilator | 1/47 (2.13) | 1/35 (2.86) | 0 |